

Supplementary Materials:

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes

Charline Lafayolle de la Bruyère <sup>1,\*</sup>, Pierre Jean Souquet <sup>2,3,4</sup>, Stéphane Dalle <sup>2,3,5</sup>, Pauline Corbaux <sup>1</sup>, Amélie Boespflug <sup>2,3,5</sup>, Michaël Duruisseaux <sup>2,3,6</sup>, Lize Kiakouama-Maleka <sup>2,3,7</sup>, Thibaut Reverdy <sup>1</sup>, Madeleine Maugeais <sup>1</sup>, Gulsum Sahin <sup>3</sup>, Denis Maillet <sup>1,2,3</sup> and Julien Péron <sup>1,2,3,8</sup>




Figure S1 : Overall survival (OS) depending on the use of glucocorticoids or not in patients with grade 3 and more immune-related adverse events (irAEs).




Figure S2 : Progression free survival (PFS) depending on the use of glucocorticoids or not in patients with grade 3 and more irAEs.




Figure S3 : OS depending on the interruption of immune check-point inhibitors or not in patients with grade 3 and more irAEs.




Figure S4 : PFS depending on the interruption of immune check-point inhibitors or not in patients with grade 3 and more irAEs.